Health Care · Life Sciences Tools & Services · US stock · price as of 16 Oct 2026
Key indicators
Price
$172.97
52-week range
$107.98 – $177.47
Market cap
$49.0B
P/E (trailing)
34.1×
EV / EBITDA
26.8×
Free-cash-flow yield
2.6%
Dividend yield
0.6%
Revenue (last 12 months)
$7.4B
Revenue growth (3y a year)
0.5%
Operating margin
22.2%
Return on invested capital
14.6%
Net debt / EBITDA
1.3×
Fair value
Blended fair value$122.52 range $117 – $127
Versus priceOvervalued−29% to fair value
Peer multiples
$132.76
Fundamentals-adjusted multiple
$122.42
10-year DCF (market-scaled)
$112.37
Earnings power value (floor, not blended)
$48.39
Model uncertainty
Medium
X-Ray Score
42/ 100 · High confidence · ahead of 27% of sector peers
Valuation29
Growth35
Profitability52
Financial health50
Dividends50
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Agilent Technologies provides instruments, software, consumables and services for laboratories. Its products include liquid and gas chromatography systems, mass spectrometers, genomic and cell analysis tools, and diagnostic tests and reagents. Customers work in pharmaceuticals, diagnostics, chemicals, food testing, environmental testing and academic research. The company is organised into life sciences and applied markets, diagnostics and genomics, and a laboratory services business.
Agilent earns revenue from new instruments and from the recurring consumables, service contracts and software that laboratories use with them. Over the last twelve months it was $7.4 billion, growing at 0.5% a year across the last three years. The operating margin is 22.2%, and the business earns a profit of 15% on the capital invested in it. It carries net debt of 1.3 times EBITDA. A dividend is paid, with a yield of 0.6%.
StocksXray gives Agilent Technologies, Inc. an X-Ray Score of 42 out of 100 (high confidence), ahead of 27% of the S&P 500 stocks in its sector. Its strongest lens is profitability (52) and its weakest is valuation (29).
Our fair value blend is $122.52 (range $117.15 to $127.36). At $172.97 the stock trades 41% above that blend, so the label is "Overvalued" with medium model uncertainty. Fair value is a range, not a price target.
XStocksXray
Agilent Technologies, Inc. (A)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$151.96
$134.35
$101.09
$128.30
$145.27
$172.97
Market cap
$46.7B
$40.3B
$29.9B
$37.3B
$41.4B
$49.0B
P/E
38.6×
32.1×
24.1×
29.0×
31.8×
34.1×
EV / revenue
7.6×
6.1×
4.5×
6.1×
6.2×
6.9×
EV / EBITDA
28.7×
21.7×
19.2×
22.6×
24.3×
26.8×
Price / free cash flow
36.0×
39.5×
20.3×
27.2×
35.9×
38.6×
Free-cash-flow yield
2.8%
2.5%
4.9%
3.7%
2.8%
2.6%
Price / book
8.7×
7.6×
5.1×
6.3×
6.1×
6.6×
Dividend yield
0.51%
0.63%
0.89%
0.74%
0.68%
0.59%
Fundamentals checklist ● 3 Good · ● 8 Average · ● 5 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−1.2%Bad
Free-cash-flow yield2.6%Bad
Risk models
Altman Z score3.5×Average
Piotroski F-Score5 of 9Bad
Growth
EPS growth (3y)3.0%Average
Free-cash-flow growth (3y)4.1%Average
Revenue growth (3y)0.5%Bad
Growth consistency80%Bad
Balance sheet
Current ratio2.1×Good
Net debt / EBITDA1.3×Good
Interest cover15.5×Average
Valuation
Fair value vs price0.7×Average
EBIT / EV yield3.2%Average
Profitability
Return on invested capital14.6%Average
Operating margin22.2%Good
Gross profitability28.4%Average
XStocksXray
Agilent Technologies, Inc. (A)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
6,319
6,848
6,833
6,510
6,948
7,372
Gross profit
3,407
3,722
3,465
3,535
3,643
3,968
Operating income
1,347
1,618
1,350
1,488
1,479
1,639
Net income
1,210
1,254
1,240
1,289
1,303
1,440
Diluted EPS ($)
3.94
4.18
4.19
4.43
4.57
5.07
Free cash flow
1,297
1,021
1,474
1,373
1,152
1,267
Gross margin
53.9%
54.4%
50.7%
54.3%
52.4%
53.8%
Operating margin
21.3%
23.6%
19.8%
22.9%
21.3%
22.2%
Net margin
19.1%
18.3%
18.1%
19.8%
18.8%
19.5%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
10,705
10,532
10,763
11,846
12,727
13,967
Cash
1,484
1,053
1,590
1,329
1,789
1,758
Total debt
2,729
2,769
2,735
3,390
3,354
3,949
Equity
5,389
5,305
5,845
5,898
6,741
7,363
Dividend per share ($)
0.78
0.84
0.90
0.94
0.99
1.01
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.